Use and cost of erythropoiesis-stimulating agents in patients with cancer

Current Medical Research and Opinion

Volumn 25, Issue 7, 2009, Pages 1775-1784

  Daniel, Gregory ^a   Hurley, Dana ^b   Whyte, Joanna L ^b   Willey, Vincent ^c   Wilson, Marcus ^a   Kallich, Joel ^b  

^a HEALTHCORE INC   (United States)

^b AMGEN INC   (United States)

^c UNIVERSITY OF THE SCIENCES   (United States)

Author keywords

Anemia; Erythropoietin stimulating agent; Retrospective study; Treatment costs

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DACARBAZINE; DACTINOMYCIN; DAUNORUBICIN; DOXORUBICIN; FLUOROURACIL; GEMCITABINE; IFOSFAMIDE; METHOTREXATE; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT ERYTHROPOIETIN; TAXANE DERIVATIVE; VINBLASTINE; VINCRISTINE;

ADVERSE DRUG REACTION; ANEMIA; ARTICLE; CHEMOTHERAPY INDUCED ANEMIA; CONTROLLED STUDY; COST BENEFIT ANALYSIS; DRUG DOSE COMPARISON; DRUG DOSE REGIMEN; DRUG USE; HEALTH CARE COST; HEALTH INSURANCE; HUMAN; OUTPATIENT CARE; RETROSPECTIVE STUDY; SENSITIVITY ANALYSIS; TREATMENT DURATION;

ADULT; AGED; AGED, 80 AND OVER; ANEMIA; DOSE-RESPONSE RELATIONSHIP, DRUG; EPOETIN ALFA; ERYTHROPOIETIN; FEMALE; HEALTH CARE COSTS; HEMATINICS; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 67650485759     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007990903001150     Document Type: Article

References (31)

1. Birgegard G, Aapro MS, Bokemeyer C, et al. Cancer-related anemia: pathogenesis, prevalence and treatment. Oncology 2005;68(Suppl 1):3-11
2. Groopman JE, Itri LM. Chemotherapy-induced anemia in adults: incidence and treatment. J Natl Cancer Inst 1999;91:1616-34
3. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology v.1.2008. Available at http://www.nccn.org/professionals/physician- gls/PDF/anemia.pdf (Last accessed May 2008) 2008
4. Demetri GD, Kris M, Wade J, et al. Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: results from a prospective community oncology study. J Clin Oncol 1998;16:3412-25
5. Gabrilove JL, Cleeland C, Livingston RB, et al. Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: improvements in hemoglobin and quality of life are similar to three-times-weekly dosing. J Clin Oncol 2001;19:2875-82
6. Vansteenkiste J, Tomita D, Rossi G, et al. Darbepoetin alfa in lung cancer patients on chemotherapy: a retrospective comparison of outcomes in patients with mild versus moderate-to-severe anaemia at baseline. Support Care Cancer 2004;12:253-62
7. Littlewood TJ, Kallich JD, San Miguel J, et al. Efficacy of darbepoetin alfa in alleviating fatigue and the effect of fatigue on quality of life in anemic patients with lymphoproliferative malignancies. J Pain Symptom Manage 2006;31:317-25
8. Tchekmedyian NS, Kallich J, McDermott A, et al. The relationship between psychologic distress and cancer-related fatigue. Cancer 2003;98:198-203
9. Amgen Inc. Aranesp (darbepoetin alfa) prescribing information. Thousand Oaks, CA, 2009
10. Ortho Biotech Products L.P. Procrit (epoetin alfa) prescribing information. Bridgwater, NJ, 2009
11. Canon JL, Vansteenkiste J, Bodoky G, et al. Randomized, double-blind, active-controlled trial of every-3-week darbepoetin alfa for the treatment of chemotherapy-induced anemia. J Natl Cancer Inst 2006;98:273-84
12. Glaspy J, Vadhan-Raj S, Patel R, et al. Randomized comparison of every-2-week darbepoetin alfa and weekly epoetin alfa for the treatment of chemotherapy-induced anemia: the 20030125 Study Group Trial. J Clin Oncol 2006;24:2290-7
13. Sasu BJ,Hartley C, Schultz H, et al. Comparison of epoetin alfa and darbepoetin alfa biological activity under different administration schedules in normal mice. Acta Haematol 2005;113:163-74
14. Macdougall IC, Gray SJ, Elston O, et al. Pharmacokinetics of novel erythropoiesis stimulating protein compared with epoetin alfa in dialysis patients. J Am Soc Nephrol 1999;10:2392-5
15. Egrie JC, Dwyer E, Browne JK, et al. Darbepoetin alfa has a longer circulating half-life and greater in vivo potency than recombinant human erythropoietin. Exp Hematol 2003;31:290-9
16. Cersosimo RJ, Jacobson DR. Epoetin alfa versus darbepoetin alfa in chemotherapy-related anemia. Ann Pharmacother 2006;40:58-65
17. Schwartzberg L, Shiffman R, Tomita D, et al. A multicenter retrospective cohort study to compare the utilization patterns and clinical outcomes of erythropoietic proteins for chemotherapy-induced anemia. Clin Ther 2003;25:2781-96
18. Patton J, Reeves T, Wallace J. Effectiveness of darbepoetin alfa versus epoetin alfa in patients with chemotherapy-induced anemia treated in clinical practice. Oncologist 2004;9:451-8
19. Herrington JD, Davidson SL, Tomita DK, et al. Utilization of darbepoetin alfa and epoetin alfa for chemotherapy-induced anemia. Am J Health Syst Pharm 2005;62:54-62
20. Lefebvre P, Gosselin A, McKenzie RS, et al. Dosing patterns, treatment costs, and frequency of physician visits in adults with cancer receiving erythropoietic agents in managed care organizations. Curr Med Res Opin 2006;22:1623-31
21. Berger A, Edelsberg J, Kallich J, et al. Use of darbepoetin alfa and epoetin alfa in clinical practice in patients with cancerrelated anemia. Clin Ther 2008;30:1-12
22. Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987;40:373-83
23. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 1992;45:613-19
24. Duan N. Smearing estimate: a nonparametric retransformation technique. J Am Stat Assoc 1983;78:605-10
25. Glaspy JA, Jadeja JS, Justice G, et al. Darbepoetin alfa given every 1 or 2 weeks alleviates anaemia associated with cancer chemotherapy. Br J Cancer 2002;87:268-76
26. Hedenus M, Adriansson M, San Miguel J, et al. Efficacy and safety of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies: a randomized, double-blind, placebocontrolled study. Br J Haematol 2003;122:394-403
27. Vadhan-Raj S, Mirtsching B, Charu V, et al. Assessment of hematologic effects and fatigue in cancer patients with chemotherapy-induced anemia given darbepoetin alfa every two weeks. J Support Oncol 2003;1:131-8
28. Vansteenkiste J, Pirker R, Massuti B, et al. Double-blind, placebo-controlled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy. J Natl Cancer Inst. 2002;94:1211-20
29. Waltzman R, Croot C, Justice GR, et al. Randomized comparison of epoetin alfa (40000U weekly) and darbepoetin alfa (200 microg every 2 weeks) in anemic patients with cancer receiving chemotherapy. Oncologist 2005;10:642-50
30. Schwartzberg LS, Yee LK, Senecal FM, et al. A randomized comparison of every-2-week darbepoetin alfa and weekly epoetin alfa for the treatment of chemotherapy-induced anemia in patientswith breast, lung, or gynecologic cancer. Oncologist 2004;9:696-707
31. Reed SD, Radeva JI, Daniel DB, et al. Economic evaluation of weekly epoetin alfa versus biweekly darbepoetin alfa for chemotherapy-induced anaemia: evidence from a 16-week randomised trial. Pharmacoeconomics 2006;24:479-94